SPARC Sun Pharma Advanced Research Company Q2 FY25 results (Jul–Sep 2024) and concall
SPARC held a general business update call, outlining a strategic pivot following the negative full results of its PROSEEK study. The company is now focusing its resources on two anchor assets, SCD-153 for autoimmune conditions and SBO-154, a novel MUC-1 ADC for oncology, with several clinical milestones targeted for FY26-FY27. Facing resource constraints, SPARC is actively pursuing short-term cash catalysts, including a potential Pediatric Rare Disease Voucher for Sezaby valued over 150 million USD and a CML program partnership, while also adjusting its operational structure with significant h
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 13 |
| EBITDA | -103 |
| Net profit | -107 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
